Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by WIJNANDS, M. J. H.
Right arrow Articles by VAN RIEL, P. L. C. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by WIJNANDS, M. J. H.
Right arrow Articles by VAN RIEL, P. L. C. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1993 British Society for Rheumatology

other

RHEUMATOID ARTHRITIS: A RISK FACTOR FOR SULPHASALAZINE TOXICITY? A META-ANALYSIS

M. J. H. WIJNANDS*,, M. A. VAN 'T HOF{dagger}, L. B. A. VAN DE PUTTE* and P. L. C. M. VAN RIEL*

*Departments of Rheumatology, University Hospital Nijmegen The Netherlands
{dagger}Departments of Medical Statistics, University Hospital Nijmegen The Netherlands

Correspondence to: Correspondence to M. J. Wijnands, University Hospital Nijmegen, PO Box 9101, 6500 HB Nijmegen, The Netherlands

The disease RA itself is assumed to be a risk factor for the occurrence of adverse drug reactions during sulphasalazine therapy. A meta-analysis comparing treatment termination because of toxicity among RA, inflammatory bowel disease and seronegative spondylarthropathy patients was conducted. It is shown that RA itself does not appear to predispose to treatment discontinuation because of adverse reactions. Differences found in the incidence of side effects among the various disease groups can probably be explained by patient selection, particularly with respect to age, proportion treated for the first time with sulphasalazine, and dosage used. The side effect profiles in the three groups studied are not different. However, a trend towards greater haematological and hepatic toxicity in rheumatic patients is noticed.

KEY WORDS: Sulphasalazine toxicity, Rheumatoid arthritis, Inflammatory bowel disease, Seronegative spondylarthropathy, Risk factor, Meta-analysis


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.